Table 1.

Patient characteristics

0.3 mg/g LUT014 gel (N = 3)1.0 mg/g LUT014 gel (N = 4)2.5 mg/g LUT014 gel (N = 3)Total (N = 10)
Age (years)
 Median67505554
 Range53–7042–6649–6742–70
Gender
 Female2002
 Male1438
Race
 Black or African American0101
 White3328
 Other0011
Stage
 IVa2316
 IVb1124
EGFR inhibitor antibody
 Cetuximab1214
 Panitumumab2226
EGFR inhibitor treatment of metastatic colorectal carcinoma—number of days prior to screening visit that treatment initiated
 Median571064257
 Range3–7928–2658–693–265